[1]赵昕锐,王 丹,刘春平,等.HA树脂血液灌流联合血液透析治疗终末期肾病的成本-效果分析[J].卫生经济研究,2023,40(8):40-44.
　ZHAO Xinrui,WANG Dan,LIU Chunping,et al.Cost-effectiveness Analysis of HA Resin Hemoperfusion combined with Hemodialysis in the Treatment of End-stage Renal Disease[J].Journal Press of Health Economics Research,2023,40(8):40-44.
点击复制

HA树脂血液灌流联合血液透析治疗终末期肾病的成本-效果分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
40
期数:
2023年8期
页码:
40-44
栏目:
成本与价格
出版日期:
2023-07-26

文章信息/Info

Title:
Cost-effectiveness Analysis of HA Resin Hemoperfusion combined with Hemodialysis in the Treatment of End-stage Renal Disease
作者:
赵昕锐1; 王 丹2; 刘春平3; 赵 琨3; 高晶磊3
1.中国药科大学国际医药商学院，江苏 南京 211198
2.北京大学口腔医院国家口腔医学中心、国家口腔医学中心、国家口腔疾病临床医学研究中心、口腔数字化医疗技术和材料国家工程实验室，北京 100081
3.国家卫生健康委卫生发展研究中心、国家药物与卫生技术综合评估中心，北京 100044
Author(s):
ZHAO Xinrui;  WANG Dan;  LIU Chunping;  ZHAO Kun;  GAO Jinglei
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
终末期肾病; 血液灌流; 血液透析; Markov模型; 成本-效果分析
Keywords:
End-stage renal disease;  hemoperfusion;  hemodialysis;  Markov model;  cost-effectiveness analysis
分类号:
R19
文献标志码:
A
摘要:
目的：比较血液灌流联合血液透析治疗终末期肾病与常规血液净化的经济性，为相关卫生决策提供参考。方法：建立Markov模型，按照是否发生心血管事件，分别模拟终末期肾病患者的疾病进展；治疗方案疗效来源于两项HA树脂血液灌流多中心临床试验研究，成本数据来自真实世界数据，健康状态效用值从文献研究中提取或计算；采用敏感性分析检测模型基础结果的稳定性。结果：相比常规血液净化，采用HA树脂血液灌流联合血液透析治疗的终末期肾病患者在获得更多QALY的同时成本也较高，增量成本-效果比为196 992.12元/QALY，但小于中国3倍人均GDP。结论：对采用维持性血液透析治疗的终末期肾病患者，增加HA树脂血液灌流治疗具有一定的经济性。
Abstract:
Objective To compare the economy of hemoperfusion combined with hemodialysis in the treatment of end-stage renal disease with that of conventional blood purification, and to provide reference for relevant health decisions. Methods The Markov model was constructed to simulate the disease progression of patients with end-stage renal disease based on whether cardiovascular events occur. The curative effect of the treatment scheme was obtained from two multicenter clinical trials of HA resin hemoperfusion. The cost data were derived from real world data, and the utility value of health status was extracted or calculated from literature research. Sensitivity analysis was performed to verify the stability of the base case results of the model. Results Compared with conventional blood purification, patients with end-stage renal disease treated with HA resin Hemoperfusion combined with hemodialysis have more QALY and higher costs. The incremental cost-effectiveness ratio was 196 992.12 yuan/QALY, but it was less than three times per capita GDP in China. Conclusion For patients with end-stage renal disease treated with maintenance hemodialysis, it is economical to add HA resin Hemoperfusion treatment.

参考文献/References:

[1] Lv J C,Zhang L X.Prevalence and Disease Burden of Chronic Kidney Disease[J].Adv Exp Med Biol,2019（1165）:3-15.
[2] 肖月，隋宾艳，赵琨.我国终末期肾病现状及透析技术的应用、费用及支付情况分析[J].中国卫生政策研究，2011，4（5）：29-33.
[3] Liyanage T,Ninomiya T,Jha V,et al.Worldwide access to treatment for end-stage kidney disease:a systematic review[J].Lancet,2015, 385(9981):1975-1982.
[4] 李菊，李建兰，高爱民.中国终末期肾病患者行维持性血液透析的流行病学现况[J].实用临床医药杂志，2018，22（21）：160-162.
[5] 景三辉，高丹，吴歌.终末期肾脏病不同透析方式患者经济负担比较[J].河南医学研究，2016，25（9）：1545-1547.
[6] 唐俊，左满花，黄德斌.不同血液净化模式对终末期肾病患者的自身免疫、炎症应激及生活质量的影响[J].中国现代医学杂志，2017，27（28）：22-28.
[7] 张传洪.终末期肾病血液净化治疗的应用与预后分析[J].中国社区医师，2019，35（26）：65-66.
[8] 张伟明.血液灌流联合常规血液净化治疗ESRD：2011中华医学会肾脏病学分会血液净化论坛暨黑龙江省医学会肾脏病学年会， 哈尔滨，2011[C].
[9] Goicoechea M,de Vinuesa S G,Gmez-Campder F,et al.Predictive cardiovascular risk factors in patients with chronic kidney disease(CKD)[J].Kidney Int Suppl,2005(93):S35-S38.
[10] 肖月，赵琨，隋宾艳，等.终末期肾病血液透析和腹膜透析治疗经济学评价研究综述[J].中国卫生经济，2012，31（2）：62-64.
[11] 谢小萍，何强，李贵森，等.终末期肾病血液透析和腹膜透析的经济学评价[J].卫生经济研究，2014（7）：43-48.
[12] Pattanaprateep O,Ingsathit A,McEvoy M,et al.Cost-Effectiveness Analysis of Renin-Angiotensin Aldosterone System Blockade in Progression of Chronic Kidney Disease[J].Value Health Reg Issues, 2018(15):155-160.
[13] Davies E W,Matza L S,Worth G,et al.Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis[J].Health Qual Life Outcomes, 2015(13):90.
[14] 周挺，李洪超，马爱霞，等.药物经济学评价中生命终末期患者意愿支付阈值探讨[J].卫生经济研究，2018，35（3）：55-57, 60.

更新日期/Last Update: 2023-07-26